
As of May 19, 2020, there are in total 4,986,200 laboratory-confirmed Coronavirus disease-2019 (COVID-19) cases. 2% (45,425) out of 2,657,390 active COVID-19 cases are critically ill and might be requiring intensive care support. Unfortunately, even after six months since its first detection, we still do not have any definitive treatment options for COVID-19 pneumonia. Recently, the use of human convalescent plasma is being considered as a potential option for the treatment of COVID-19.
convalescent plasma therapy, coronavirus, Immunization, Passive, COVID-19, Infectious Disease, Hematology, Therapeutics, Severity of Illness Index, Infectious Diseases, Medical Microbiology, Virus Diseases, Virology, Humans, Fluids and Secretions, COVID-19 Serotherapy
convalescent plasma therapy, coronavirus, Immunization, Passive, COVID-19, Infectious Disease, Hematology, Therapeutics, Severity of Illness Index, Infectious Diseases, Medical Microbiology, Virus Diseases, Virology, Humans, Fluids and Secretions, COVID-19 Serotherapy
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 18 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Top 10% | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Top 10% | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Top 10% |
